BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38384458)

  • 1. Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions.
    Nabors LB; Lamb LS; Goswami T; Rochlin K; Youngblood SL
    Front Immunol; 2024; 15():1299044. PubMed ID: 38384458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
    Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
    PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
    Lamb LS; Pereboeva L; Youngblood S; Gillespie GY; Nabors LB; Markert JM; Dasgupta A; Langford C; Spencer HT
    Sci Rep; 2021 Oct; 11(1):21133. PubMed ID: 34702850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
    Weiss T; Schneider H; Silginer M; Steinle A; Pruschy M; Polić B; Weller M; Roth P
    Clin Cancer Res; 2018 Feb; 24(4):882-895. PubMed ID: 29162646
    [No Abstract]   [Full Text] [Related]  

  • 5. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
    Zhou J; Tong F; Zhao J; Cui X; Wang Y; Wang G; Kang C; Liu X; Wang Q
    Cancer Biol Med; 2023 Jun; 20(5):385-400. PubMed ID: 37283490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
    Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H
    J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
    Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
    BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
    Xin L; Tan Y; Zhu Y; Cui X; Wang Q; Zhao J; Tian S; Xu C; Xiao M; Hong B; Xu J; Yuan X; Wang C; Kang C; Fang C
    Neuro Oncol; 2023 Nov; 25(11):1976-1988. PubMed ID: 37279651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
    Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
    ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
    Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
    Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q; Berglund AE; Macaulay RJ; Etame AB
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
    Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
    Tomar MS; Kumar A; Srivastava C; Shrivastava A
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188616. PubMed ID: 34419533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
    Wang HW; Xu ZK; Song Y; Liu YG
    Cancer Gene Ther; 2017 May; 24(5):215-220. PubMed ID: 28409559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.